MedPath

LIEBEL-FLARSHEIM COMPANY LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

99

Active:51
Completed:36

Trial Phases

5 Phases

Phase 1:35
Phase 2:4
Phase 3:9
+2 more phases

Drug Approvals

42

NMPA:35
FDA:6
EMA:1

Drug Approvals

Ioversol Injection

Product Name
安射力350
Approval Number
国药准字HJ20150334
Approval Date
May 31, 2024
NMPA

Ioversol Injection

Product Name
安射力320
Approval Number
国药准字HJ20150338
Approval Date
May 30, 2024
NMPA

Ioversol Injection

Product Name
安射力350
Approval Number
国药准字HJ20150332
Approval Date
May 30, 2024
NMPA

Iodinated Oil Injection

Product Name
Lipiodol Ultra Fluide
Approval Number
国药准字HJ20171362
Approval Date
Nov 16, 2022
NMPA

Iobitridol Injection

Product Name
三代显
Approval Number
国药准字HJ20160376
Approval Date
Jun 8, 2021
NMPA

Iobitridol Injection

Product Name
三代显
Approval Number
国药准字HJ20160374
Approval Date
Jun 8, 2021
NMPA

Iobitridol Injection

Product Name
三代显
Approval Number
国药准字HJ20160375
Approval Date
Jun 8, 2021
NMPA

Iobitridol Injection

Product Name
三代显
Approval Number
国药准字HJ20160377
Approval Date
Jun 8, 2021
NMPA

Iobitridol Injection

Product Name
三代显
Approval Number
国药准字HJ20160373
Approval Date
Jun 8, 2021
NMPA

Gadoteric Acid Meglumine Salt Injection

Product Name
多它灵
Approval Number
国药准字HJ20160126
Approval Date
Feb 10, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

Clinical Trials

Distribution across different clinical trial phases (70 trials with phase data)• Click on a phase to view related trials

Phase 1
35 (50.0%)
Phase 4
21 (30.0%)
Phase 3
9 (12.9%)
Phase 2
4 (5.7%)
Not Applicable
1 (1.4%)

Performance of Elucirem® in DSC-MRI Perfusion of Brain Gliomas

Phase 3
Completed
Conditions
Brain Tumor, Recurrent
Brain Tumor, Primary
Interventions
First Posted Date
2023-09-28
Last Posted Date
2025-05-06
Lead Sponsor
Guerbet
Target Recruit Count
138
Registration Number
NCT06057168
Locations
🇭🇺

Országos Idegtudományi Intézet - Neuroonkológiai és Intracraniá, Budapest, Hungary

🇭🇺

Semmelweis Egyetem - Neurologiai Klinika, Budapest, Hungary

🇭🇺

Debreceni Egyetem, Debrecen, Hungary

and more 8 locations

Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children

Phase 3
Completed
Conditions
Lesion in Body Region
CNS Lesion
Interventions
Drug: Comparator
First Posted Date
2023-08-24
Last Posted Date
2025-05-20
Lead Sponsor
Guerbet
Target Recruit Count
240
Registration Number
NCT06010173
Locations
🇯🇵

Meitetsu Hospital, Aichi, Japan

🇯🇵

Fukuoka University Hospital, Fukuoka, Japan

🇯🇵

Gifu University Hospital, Gifu, Japan

and more 24 locations

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

Phase 2
Completed
Conditions
Central Nervous System Diseases
Pediatric Disorder
Body Indication
Interventions
First Posted Date
2022-10-21
Last Posted Date
2025-03-28
Lead Sponsor
Guerbet
Target Recruit Count
36
Registration Number
NCT05590884
Locations
🇺🇸

Cincinnatti Childrens Hospital, Cincinnati, Ohio, United States

🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

🇭🇺

Semmelweis Egyetem, Budapest, Hungary

and more 8 locations

Safety and Performance of Optivantage Multi-use When Injecting Contrast Media for Contrast Enhanced CT Examination

Not yet recruiting
Conditions
Patient Participation
First Posted Date
2022-09-13
Last Posted Date
2022-09-13
Lead Sponsor
Guerbet
Target Recruit Count
100
Registration Number
NCT05537779

Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market Clinical Follow-up

Recruiting
Conditions
Oncology
First Posted Date
2022-04-07
Last Posted Date
2022-09-15
Lead Sponsor
Guerbet
Target Recruit Count
50
Registration Number
NCT05316077
Locations
🇦🇹

Univ.-Klinik für Radiologie, Graz, Austria

🇫🇷

CHU-Hôpital François Mitterrand, Dijon, France

🇨🇭

CHUV, Lausanne, Switzerland

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 9
  • Next

News

NUCLIDIUM's Copper-Based Radiotracer Shows Enhanced Imaging Performance in First Prostate Cancer Patient

NUCLIDIUM's 61Cu-NODAGA-PSMA I&T radiotracer successfully imaged the first patient in a phase 1 trial, showing more osseous lesions than FDA-approved 18F-piflufolastat at 1 hour post-injection.

© Copyright 2025. All Rights Reserved by MedPath